Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25770293
.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117 Clin+Cancer+Res
2015 ; 21
(6
): 1258-66
Nephropedia Template TP
gab.com Text
Twit Text FOAVip
Twit Text #
English Wikipedia
Translational implications of tumor heterogeneity
#MMPMID25770293
Jamal-Hanjani M
; Quezada SA
; Larkin J
; Swanton C
Clin Cancer Res
2015[Mar]; 21
(6
): 1258-66
PMID25770293
show ga
Advances in next-generation sequencing and bioinformatics have led to an
unprecedented view of the cancer genome and its evolution. Genomic studies have
demonstrated the complex and heterogeneous clonal landscape of tumors of
different origins and the potential impact of intratumor heterogeneity on
treatment response and resistance, cancer progression, and the risk of disease
relapse. However, the significance of subclonal mutations, in particular
mutations in driver genes, and their evolution through time and their dynamics in
response to cancer therapies, is yet to be determined. The necessary tools are
now available to prospectively determine whether clonal heterogeneity can be used
as a biomarker of clinical outcome and to what extent subclonal somatic
alterations might influence clinical outcome. Studies that use longitudinal
tissue sampling, integrating both genomic and clinical data, have the potential
to reveal the subclonal composition and track the evolution of tumors to address
these questions and to begin to define the breadth of genetic diversity in
different tumor types and its relevance to patient outcome. Such studies may
provide further evidence for drug-resistance mechanisms informing combinatorial,
adaptive, and tumor immune therapies placed within the context of tumor
evolution.
free
free
free
